SCHEMBL11233534

SCHEMBL11233534

COC(=O)C1(F)C(=O)NC(=O)NC1OC

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.36
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11245438 0.87 TP53 (0.34) TP53
SCHEMBL15413590 0.86 TP53 (0.33) TP53
SCHEMBL11250408 0.86 ALDH1A1 (0.40) TP53KMT2A
SCHEMBL11240899 0.84 ALDH1A1 (0.38) TP53
SCHEMBL11243781 0.81 TP53 (0.37) TP53KMT2A
SCHEMBL11243898 0.81 LMNA (0.35) TP53KMT2A
SCHEMBL11243254 0.79 TDP1 (0.38) KMT2A
SCHEMBL11248743 0.78 HSD17B10 (0.37) KMT2A
SCHEMBL11235707 0.78 TP53 (0.35) TP53KMT2A
SCHEMBL11245890 0.73 MEN1 (0.39) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150148292-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO UNIV EMORY (US) 2015-05-28 US claimed
WO-2014011540-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2014-01-16 WO claimed
US-4329460-A ANTICANCER AGENTS, ANTIVIRAL AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1982-05-11 US claimed
US-10933169-B2 Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto EMORY UNIVERSITY (US) 2021-03-02 US disclosed
US-10434220-B2 Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto EMORY UNIVERSITY (US) 2019-10-08 US disclosed
US-20160089478-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO UNIV EMORY (US) 2016-03-31 US disclosed
US-20150148292-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO UNIV EMORY (US) 2015-05-28 US disclosed
US-20150148292-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO UNIV EMORY (US) 2015-05-28 US disclosed
WO-2014011540-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2014-01-16 WO disclosed
WO-2014011540-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2014-01-16 WO disclosed
US-4329460-A ANTICANCER AGENTS, ANTIVIRAL AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1982-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148292-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO BMP4, BMP2, BMP1 TP53 1749/4885KMT2A 4390/4885
US-10434220-B2 Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto BMP2, BMP4, BMP1 TP53 2455/4885KMT2A 3326/4885
US-10933169-B2 Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto BMP2, BMP4, BMP1 TP53 2455/4885KMT2A 3326/4885
US-20160089478-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO BMP2, BMP4, BMP1 TP53 2455/4885KMT2A 3326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.